23andMe
therapeutics pipeline first in class potential | 23andMe
Company
Deck Type
Sector
Industry
Deck date
January 2024
Slide
21 of 39
Related slides by other companies
Fusion Pharmaceuticals
Investor Presentation
November 2023
unlocking the potential of in novel targets sey discovery | Fusion Pharmaceuticals
Fusion Pharmaceuticals
Investor Presentation
August 2023
unlocking the potential of in novel targets sty discovery | Fusion Pharmaceuticals
Erasca
Investor Presentation
November 2023
could combine synergistically with the rest of our pipeline seth i a eras | Erasca
AN2 Therapeutics
IPO
March 2022
pipeline targets high unmet needs in rare chronic and serious infectious diseases lung disease boron chemistry approach enables targeting of novel biological targets mid phase topline data japan attest as an therapeutics | AN2 Therapeutics
Other recent decks by 23andMe
See all presentations (7 decks)
Investor Presentation
April 2023
Investor Presentation
August 2022
Investor Presentation
February 2022
Investor Day
January 2022
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights